Publication|Videos|July 11, 2024

Making the Grade: Registries as Sources of Regulatory-Grade RWE

Author(s)CorEvitas

Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.

Registries are used for multiple purposes, from peri- and post-approval safety studies to comparative effectiveness studies. With choices that include multi-sponsor registries, bespoke registries, nested studies, and more, how should you determine what works best for your needs? What do regulators say about using registries to inform decision making? Industry expert Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, explains registries and how to choose the type that best meets your needs and requirements. Watch to learn more about:

  • What types of needs are met and what questions are answered by using a registry, and which registries are available;
  • What to look for in a registry and how to choose the registry type;
  • What the company sees in terms of regulatory requirements as they relate to registries, and examples of use cases for CorEvitas Registry data.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.